Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Juha Kuisma"'
Autor:
Ilkka Vihriälä, Jari Punkkinen, Tero Ylisaukko-oja, Taina Sipponen, Eija Hirsi, Christian Nielsen, Jyrki Tillonen, Markku Pajala, Jouni Silvennoinen, Ville Liukkonen, Mikko Kellokumpu, Jari Jokelainen, Henna Rautiainen, Veikko Moilanen, Hans Henricson, Hannu Sulonen, Mirva Esterinen, Timo Blomster, Kari Toljamo, Klaus Tamminen, Pauliina Molander, Airi Jussila, Jaakko Aaltonen, Juha Kuisma, Petri Mäkelä, Kalle Hakala, Margus Lääne, Kimmo Salminen, Sauli Herrala, Ulla-Maija Suhonen, Mika Puhto, Markku Peräaho, Heikki Nuutinen
Publikováno v:
Scandinavian Journal of Gastroenterology. 53:158-167
Objectives: The efficacy and tolerability of vedolizumab in the treatment of inflammatory bowel diseases (IBD) has been demonstrated in an extensive GEMINI clinical trial programme. Clinical trials represent highly selected patient populations and, t
Autor:
Klaus Tamminen, Mikko Kellokumpu, Tero Ylisaukko-oja, Sauli Herrala, Markku Peräaho, Taina Sipponen, Henna Rautiainen, Petri Mäkelä, Jari Jokelainen, Ulla-Maija Suhonen, Heikki Nuutinen, Markku Pajala, Mirva Esterinen, Margus Lääne, Mika Puhto, Christian Nielsen, Jyrki Tillonen, Veikko Moilanen, Juha Kuisma, Ville Liukkonen, Kalle Hakala, Pauliina Molander, Hannu Sulonen, Saku Torvinen, Jaakko Aaltonen, Jouni Silvennoinen, Hans Henricson, Ilkka Vihriälä, Eija Hirsi, Kari Toljamo, Airi Jussila, Jari Punkkinen, Timo Blomster, Kimmo Salminen
Publikováno v:
Biologicals : journal of the International Association of Biological Standardization. 58
Limited data is available on vedolizumab combination therapies in real-world clinical practice. Here, we evaluated the concomitant corticosteroid, immunosuppressive, and 5-aminosalicylic acid utilization of inflammatory bowel disease (IBD) patients t
Autor:
Martti Färkkilä, Timo Blomster, Markku J. Nissinen, Juha Kuisma, Taina Sipponen, Kaija-Leena Kolho, Pauliina Molander, Henna Rautiainen, Helena Kemppainen, Airi Jussila, Ritva Koskela
Publikováno v:
Journal of Crohn's and Colitis. 7:730-735
Background and aims: Deep remission, meaning clinical remission with mucosal healing (MH), with anti-tumor necrosis factor-alpha (TNF-α) agents is a new target for therapy in inflammatory bowel disease (IBD). Our aim was to study how often patients
Publikováno v:
Diseases of the Colon & Rectum. 46:1476-1483
PURPOSE: Pouchitis has been associated with abnormal bacterial flora responding to antibiotics. Dietary factors may play a role in modifying the qualitative and quantitative components of the microflora. We evaluated interactions between nutritional
Publikováno v:
Alimentary Pharmacology & Therapeutics. 17:509-515
Summary Background : Preliminary trials of probiotics in preventing recurrent chronic pouchitis have been encouraging. Aim : To investigate the efficacy of Lactobacillus GG supplementation as primary therapy for ileal pouch inflammation, and its effe
Publikováno v:
Scandinavian Journal of Gastroenterology. 37:171-176
The aim of our study was to evaluate the influence of pouchitis and villous atrophy on bone mineral density and metabolism at least 5 years after ileal pouch-anal anastomosis for ulcerative colitis (UC).Eighty-eight subjects with a J-pouch operated o
Autor:
Kimmo Salminen, Harri Mustonen, Johanna Haapamäki, Ari Ristimäki, Jari Punkkinen, Airi Jussila, Urpo Nieminen, Henna Rautiainen, Pauliina Molander, Markku J. Nissinen, Taina Sipponen, Helena Kemppainen, Martti Färkkilä, Timo Blomster, Perttu Arkkila, Kaija-Leena Kolho, Ritva Koskela, Juha Kuisma
Publikováno v:
Journal of Crohn'scolitis. 9(1)
Background and aims: This prospective multicenter study examined whether elevated fecal calprotec tin (FC) concentrations after stopping TNFα-blocking therapy can predict clinical or endoscopic relapse. In addition, we evaluated the impact of histol
Autor:
Arvi I. Kahri, Juha Kuisma, Pekka Luukkonen, Heikki Järvinen, Hannu Nuutinen, Martti Färkkilä
Publikováno v:
Europe PubMed Central
OBJECTIVES: Chronic inflammation in the ileal pouch is the most significant late complication after ileal pouch–anal anastomosis (IPAA). It leads to changes in mucosal morphology, with consequent decreased vitamin B12, bile acid and cholesterol abs
Autor:
Anna, Lepistö, Juha, Kuisma
Publikováno v:
Duodecim; laaketieteellinen aikakauskirja. 128(12)
Proctocolectomy and ileoanal anastomosis as a treatment of ulcerative colitis Sphincter-saving proctocolectomy, construction of ileal pouch (J pouch) and associated ileoanal anastomosis constitute an established surgical procedure in the treatment of
Publikováno v:
Scandinavian journal of gastroenterology. 39(6)
Pouchitis occurs in 20% to 59% of patients operated on for ulcerative colitis. Several risk factors have been identified for the development of pouchitis. This study was undertaken to assess the incidence of pouchitis at least 5 years after ileal pou